Neuropsychiatric symptoms (NPs) have been reported with dolutegravir use. We hypothesized that increasing dolutegravir trough concentrations (Ctrough) and/or polymorphism in the SLC22A2 gene, encoding the organic cation transporter-2 (OCT2), which is involved in monoamine clearance in the CNS and is inhibited by dolutegravir, might be associated with NPs.
SLC22A2 variants and dolutegravir levels correlate with psychiatric symptoms in persons with HIV
Calcagno, A;
2019-01-01
Abstract
Neuropsychiatric symptoms (NPs) have been reported with dolutegravir use. We hypothesized that increasing dolutegravir trough concentrations (Ctrough) and/or polymorphism in the SLC22A2 gene, encoding the organic cation transporter-2 (OCT2), which is involved in monoamine clearance in the CNS and is inhibited by dolutegravir, might be associated with NPs.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
OCT2 and DTG toxicity Borghetti JAC 2018.pdf
file disponibile solo agli amministratori
Licenza:
DRM non definito
Dimensione
344.53 kB
Formato
Adobe PDF
|
344.53 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
